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ABSTRACT  
The efficiency and safety of Sulpirid (50 mg twice/daily) was assessed in 563 adult patients with 6 groups of patients with irritable bowel 
syndrome (IBS) who had failed dietary therapy.  The groups included; patients without previous treatment ( n: 137), patients who had received 
a muscarinic antagonists (n: 65), an anticholinergic/benzodiazepine combination (n: 187), a tricyclic antidepressants (n: 62) , a selective 
serotonin reuptake inhibitors (SSRIs) (n: 48) and an antiflatulent (n: 64).  Patients were assessed for 6 weeks.  Sulpirid was effective and safe in 
safe in relieving the abdominalgia, anxiety, depression and bowel function.  The overall success of Sulpride in treatment of IBS was 84%.  Most 
patients who had failed muscarinic antagonists, antiflatulent and tricyclic antidepressants had > 95% improvement with Sulpride.  The success 
was 88% in those who did not receive prior therapy while it was just 77% and 72% in those who had failed SSRIs and 
anticholinergic/benzodiazepine combination.  In treatment-failures, a further 9.8% improvement was achieved with addition of a SSRI 
(Escitalopram) and an extra 3.4% with subsequent increase in Sulpride dose to 100 mg X 2 limiting failures to only 2.3%.  Tolerance of 
treatment was good and side-effects developed in 11% patients.  In conclusion: Sulpride is an effective and safe drug in IBS. 
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INTRODUCTION 
Irritable bowel syndrome (IBS) is a chronic alteration of 
colon function.  Invasive gastrointestinal (GI) diagnostics are 
often unrevealing and hence its etiology has been considered 
a functional one [1].  According to its main presentation, it 
has been classified into diarrhea-predominant, constipation-
predominant, and enterospasmodic disorders [2]. IBS is a 
common disorder affecting 10 to 15% of people in the 
developed world [3]. The aggregate cost of irritable bowel 
syndrome in the United States has been estimated at $1.7–10 
billion in direct medical costs, with an additional $20 billion 
in indirect costs, for a total of $21.7–30 billion [4]. The 
disorder is usually associated with anxiety, depression and 
mood disorder.  Hence, low dose antidepressant drugs with 
or without antispasmodics has been used for its treatment 
[5].  Nortriptyline (Pamelor), a tricyclic antidepressant 
(TCA) which inhibits the gut nerve-activity, has been used 
for its enterospastic and diarrheal disorders. On the other 
side; a selective serotonin reuptake inhibitors (SSRIs) like 
Zoloft has been used to speed the gut in constipated subjects.  
Moreover, direct antispamsmodics as well as antidiarrheal 
agents (Lopermide) and laxatives were common additives as 
well as benzodiazepine for anxiety with risk of addiction.  In 
search for an acceptable treatment for IBS; we elected to 
evaluate the role of control of anxiety rather than depression 
in management of IBS.  Hence, we conducted this study to 
evaluate the safety and efficacy of low dose of Sulpride in 
management of this disorder.  
PATIENTS AND METHODS: 
The study started from 1st of January 2014 till 31st June 
2019.  It included all patients who presented with IBS to the 
Al-Amiri nephrology center.  The latter was established at 
Al-Amiri hospital in 1976 in the center of Kuwait city.  It is 
the referral center for all patients with kidney diseases in the 
capital area of Kuwait.  It has adequate diagnostic and 
therapeutic facilities to care for both in- and out-patients 
with renal diseases and all their medical problems.  
Moreover, it acted also as a tertiary kidney center for all 
Kuwait.    
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Inclusion criteria for IBS patients: 
Patients were included, in the study, if they fulfilled Rome IV 
criteria which include recurrent abdominal pain, on average, 
at least 1 day/week in the last 3 months, associated with 
defecation or associated with change in the frequency of 
defecation or appearance of stool [6].  
Exclusion criteria: 
1- Patients older than 50 years at start of symptoms or 
less than 14 years. 
2- Those with nocturnal pains and weight loss.   
3- Patients with GI reflux disease, peptic disease, 
Helicobacter infestation, coeliac disease (tested by 
both serological markers and biopsy of second part of 
duodenum), and inflammatory bowel disease.  
Moreover, patients with gall stones, gynecological 
disorders, autoimmune diseases and endocrine 
abnormalities.  Hence all patients had normal: full 
blood testing, liver function tests, ESR, urine routine 
and microscopy, stool analysis, ultrasound of the 
abdomen and pelvis, upper and lower gastrointestinal 
endoscopy.  TSH and Free T4 were done in all patients 
and tests for other endocrine glands as well as and 
autoimmune system when indicated. 
4- Patients with creatinine clearance < 60 ml/minute.   
Study design: 
Patients were included in the study if they did not receive 
prior treatment for IBS as well as those who had had failed 
previous drug-therapy.  All patients had instructions 
regarding dietary measures that included increasing soluble 
fiber intake, gluten-free diet and avoidance of fermentable 
sugars for 6 weeks.   Patients who did not improve or had 
failed other treatments were included in the study.  Initially, 
all patients were treated, exclusively, with Sulpride 50 mg 
X2 for 6 weeks.  Failures were further retested after addition 
of Escitalopram up to 20 mg at night to Sulpride 50 mg X2 
for another 6 weeks.  Furthermore, subsequent failures were 
retested after increasing the dose of Sulpride dose to 100 mg 
twice/daily in addition to Escitalopram.   
Statistical analysis: 
Since the age and duration of IBS prior to treatment were 
not normally distributed: (a) the median and (interquartile 
range) were used to express the groups and (b) Kruskal-
Wallies test was used to compare the difference between 
groups.   
RESULTS 
Over the past 4 and 1/2 years, a total of 2371 patients were 
screened.  Symptoms of significant IBS were detected in 577 
patients (24%).  Fourteen patients lost follow up.  The 
demographical data on the remaining 563 patients are 
summarized in (Table 1).  All patients were adults with a 
median age of 32(11) and youngest was 18 and eldest was 
46 years.  Gender distribution was (Female/Male: 1.9).  The 
median of duration of IBS prior to the study was 6(4) years 
and shortest was 2 and longest was 18 years.   
Study population: 
A 137 patients did not receive prior treatment for IBS while 
others had treatment-failure with; Mebevirine HCl 
(Duspatalin) as a muscarinic antagonists (n: 65), 
Chlordiazepoxide/clidinium bromide (Librax) as an 
anticholinergic/benzodiazepine combination (n: 187), 
Nortriptyline (Pamelor) as a TCA (n: 62), Sertraline (Zoloft) 
as a SRRI (n: 48) and Simithicone as an antiflatulent (n: 64).  
There was no statistical difference between the 6 groups 
with regards age and duration of IBS before entering the 
study. 
Efficacy of 6 weeks of Sulpride: 
The overall success of Sulpride in treatment of IBS was 84%.  
Most patients who had failed muscarinic antagonists, 
antiflatulents and TCAs had improvement with Sulpride (> 
95%).  The success was also acceptable in those who did not 
receive prior therapy (88%).   However, the success rate was 
just 77% and 72% in those who had failed SSRI and 
anticholinergic/benzodiazepine combinations. 
Management of the initial non-responders: 
An additional 9.8% improvement was achieved with 
additional of Escitalopram and further 3.4% with increasing 
Sulpride dose to 100 mg X 2 leaving only 2.3% treatment 
failure.   
Treatment side-effects:   
Sulpride produced gynecomastia in 2 males and 
galactorrhea with amenorrhea in 8 conception-seeking 
females.  It was entered as a treatment failure and the drug 
was discontinued. The extrapyramidal (Parkinsonian 
tremors) and anticholinergic side-effects were rarely seen at 
our adult population.  Sedation limited increment of the dose 
of Escitalopram to > 10 mg daily in 6 patients.   
Final treatment failures: 
Ten patients could not tolerate Sulpride therapy for side-
effects and 3 were true treatment failure.   
DISCUSSION 
The pathophysiology of IBS is uncertain.  Theories include 
genetic mutations, abnormal GI motility, enhanced gut pain 
sensation (visceral hypersensitivity, bacterial flora 
overgrowth and psychological changes [7]. One theory 
concerning the pathophysiology of IBS involves the 
neurotransmission between the central nervous system 
(CNS) and the intestines.  Numerous structures in the CNS 
connect to the gut through serotonergic nerves that help 
regulate its motility, sensation, and secretion. In patients 
with IBS, an imbalance in the function of serotonin leads to 
the deregulation of intestinal motility. Based on this 
serotonin imbalance theory, various treatment approaches 
have been suggested [8]. The most widely used 
antidepressants in IBS are TCAs and SSRIs, as they reduce 
pain and improve global IBS symptoms. Their analgesic and 
anxiolytic effect is thought to improve GI motility and 
function. However, in a recent meta-analysis of multiple 
studies, nearly half of patients were refractory to both 
treatments [9, 10].  Local anticholinergic-antispasmodics 
such as Mebevirine, hyoscyamine, dicyclomine and 
belladonna have been utilized, for short term, relief of 
abdominal pain.  However, common side-effects viz. dry 
mouth, dizziness, blurry vision, and urinary retention limit 
their long-term use especially in the elderly [11].  Moreover, 
major health concerns faced multiple drugs viz. (a) 
Alosetron, a 5-HT3 receptor antagonist used for treatment of 
IBS-D due to ischemic colitis (b) Tegaserod, a 5-HT4 receptor 
agonist, used for treatment of IBS-C due to increased risk of 
heart attack and stroke (c) Lubiprostone, a chloride channel 
activator for the management of IBS-C due to pregnancy 
teratogenicity (d) linaclotide,  a guanylate cyclase (GC-C) 
agonist and acts locally in the intestine due to concerns in 
pediatric patients and deaths in young juvenile mice and (e) 
Loperamide, a widely available OTC product, has shown to 
reduce GI transit time and improve diarrhea and urgency. 
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However, it did not improve abdominal pain and global IBS 
symptoms [11, 12].  Dietary modification included; (a) 
exclusion of  beans, alcohol, caffeine, and fatty meals, and 
gas-producing foods such as broccoli, legumes, cabbage, and 
avocado in diet and increase intake of dietary fiber 
ispaghula/psyllium (e.g. Metamucil) in constipated patients 
[13], (b)  probiotics, containing Bifidobacterium,  to prevent 
overgrowth of pathogenic GI bacteria in and reduce its 
triggering local inflammation [14], (c)  Rifaximin, a locally-
acting antibiotic used for traveler’s diarrhea and hepatic 
encephalopathy since bacterial resistance and side effects 
were a major concern [15], and carminatives (Simithicone) 
as anti-foaming agent that decrease the surface tension of 
gas bubbles, causing them to combine into larger bubbles in 
the gut [16].   
In our study, we elected to use a systemic a non-addicting 
anxiolytic agent since patients with IBS have multiple bodily 
symptoms (somatization) i.e. not a simple GI disorder [17].  
Hence, we elected to use Sulpride.  The drug is an atypical 
antipsychotic medication of the benzamide class.  At high-
doses, it is being used for treatment of psychosis associated 
with schizophrenia, major depressive disorders and panic 
attacks.  However, in low-dosage it is an excellent anxiolytic 
agent.  Contrary to benzodiazipines it is not associated with 
dependence, tolerance, hypoventilation and sleepiness [18].  
It is a selective antagonist at dopamine D2, D3 and 5-HT1A 
receptors.  Antagonism at 5-HT1A dominates in doses 
exceeding 600 mg daily.  In low doses, 50-20 mg daily, its 
prominent feature is antagonism of presynaptic inhibitory 
dopamine and serotonin receptor, accounting for some anti-
depressant activity as well as stimulatory effect [19]. 
Moreover, its beneficial effects include; activation of the 
endogenous gamma-hydroxbutyrate receptor in vivo at 
therapeutic concentrations, their upregulation in animal 
studies and activation of their DNA demethylation in the 
brain [19-21].  The drug was well tolerated and produced 
few side-effects (10%).  Hyperprolactinemia, leading to 
gynecomastia in males and galactorrhea with amenorrhea in 
conception-seeking females limited its use.  Moreover, its 
extrapyramidal (Parkinsonian tremors) and anticholinergic 
side-effects were rarely seen at our adult population [18].   
To improve the rate of success we elected first to add 
Escitalopram.  The latter is a SSRI with limited 
anticholinergic side-effects yet with potent anti-somatoform 
effect [22].  Finally, patients who did not respond to 
Sulpride- Escitalopram combination had to be treated with 
higher dosage of Sulpride and it further improved the 
success rate.  In our study, we elected to avoid high-
maintenance dosage of Sulpride to avoid its short and long-
term side-effects. In conclusion; Sulpride is a safe and 
efficacious agent in management of IBS. 
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Table 1.  Showing the results of Sulpride treatment in patients with IBS* 
                     
 
Group 
 
No. 
 
Age † 
 
Sex Duration of † Previous treatment 
 
Sulpride 50 mg X 2 
   
Further 
management 
   
    
(years) 
 
M/F 
 
IBS 
 
(> 3 months) 
 
Improved 
 
No 
change 
 
(+) 
Cipralex 
 
Sulpride 100 mg 
X2 
 
Failed 
 
1 
 
137 
 
32(12) 
 
43/94 
 
6(4) 
 
None 
 
121 (88%) 
 
16 
 
10 
 
3 
 
3 
 
                      
2 
 
65 
 
32(12) 
 
23/42 
 
6(3) 
 
Direct gut antispasmodics ** 
 
63 (97%) 
 
2 
 
2 
 
0 
 
0 
 
                      
3 
 
187 
 
32(13) 
 
57/130 
 
6(4) 
 
Anticholinergic+benzodiazepine 
*** 
 
134 (72%) 
 
53 
 
35 
 
12 
 
6 
 
                      
4 
 
62 
 
32(11) 
 
28/34 
 
6(5) 
 
Tricyclic antidepressants □ 
 
59 (95%) 
 
3 
 
3 
 
0 
 
0 
 
                      
5 
 
48 
 
34(13) 
 
26/22 
 
6(4) 
 
SSRI □□ 
 
37 (77%) 
 
11 
 
3 
 
4 
 
4 
 
                      
6 
 
64 
 
32(11) 
 
18/46 
 
6(4) 
 
Antiflatulents □□□ 
 
62 (97%) 
 
2 
 
2 
 
0 
 
0 
 
                      
Total (%) 563 
 
32(11) 
 
195/368 
 
6(4) 
   
476 (84.5%) 
 
87 
(15.5%) 
 
55 (9.8%) 
 
19 (3.4%) 
 
13 
(2.3%) 
 
* Sequential treatment: Sulpride 50 mg X2 for 6weeks then failures had Escitalopram for additional 6 weeks 
      
    
     then failures had increment of Sulpride dose to 100 mgX2 for extra 6 weeks 
        
† Age & duration of IBS are expressed in median(IQR).  
           
** Direct gut antispasmodics (muscarinic antagonist): Duspatalin 
           
*** Anticholinergic+Benzodiazepine: Chlordiazepoxide/clidinium bromide (Librax) 
          
□ Tricyclic antidepressants: Nortrtriptyline (Pamelor)  
           
□□ Selective serotonin reuptake inhibitors (SSRIs): Sertaline (Zoloft)  
           
□□□ Antiflatulents: Simithicone 
               
                      
                       
